Page 67 - TequioVol1No2

Los virus /López y Gabriel/57-67 65

Boffetta, P. y Nyberg, F. (2003). Contribution of mechanisms of viral carcinogenesis. Cancer Lett.,
environmental factors to cancer risk. Br Med Bull, 247, 182-196.
68, 71-94.
Emmett, S. R., Dove, B., Mahoney, L., Wurm, T. y
Bouchard, M. J. y Schneider, J. R. (2004). The enigmatic Hiscox, J. A. (2005). The cell cycle and virus infection.
X gene of hepatitis B virus. J. Virol., 78(23), 12725- Methods Mol Biol., 296, 197-218.
12734.
Fraga, M. F. y Esteller, M. (2005). Towards the
Bouvard, V., Baan, R., Straif, K., Grosse, Y., Secretan, human cancer epigenome: a first draft of histone
B., El Ghissassi, F., Benbrahim-Tallaa, L., Guha, N., modifications. Cell Cycle, 4, 1377-1381.
Freeman, C., Galichet, L. y Cogliano, V. (2009). A
review of human carcinogens part B: biological Fuentes-González A. M., Contreras-Paredes, A.,
agents. Lancet Oncol., 10(4), 321-322. Manzo-Merino, J. y Lizano, M. (2013). The modulation
of apoptosis by oncogenic viruses. Virol J., 10, 182.
Colditz, G. A., Wolin, K. Y. y Gehlert, S. (2012). Applying
what we know to accelerate cancer prevention. Sci. Fujimuro, M., Wu, F. Y., ApRhys, C., Kajumbula, H.,
Transl. Med., 4, 127rv4. Young, D. B., Hayward, G. S. y Hayward S. D. (2003). A
novel viral mechanism for dysregulation of b-catenin
Coussens, L. M. y Zena, W. (2002). Inflammation and in Kaposi’s sarcoma-associated herpesvirus latency.
cancer. Nature, 420, 860-867. Nat Med., 9(3), 300-306.

Croce, C. M. (2008). Oncogenes and cancer. N Engl J Ganem, D. (2006). KSHV infection and the
Med., 358, 502-511. pathogenesis of Kaposi’s sarcoma. Annu Rev Pathol
Mech Dis, 1, 273-296.
Chami, M., Ferrari, D., Nicotera, P., Paterlini-Bréchot, P.
y Rizzuto, R. (2003). Caspase-dependent alterations Genitsch, V., Novotny, A., Seiler, C. A., Kröll, D.,
of Ca2+ signaling in the induction of apoptosis by Walch, A. y Langer, R. (2015). Epstein-Barr virus in
hepatitis B virus X protein. J Biol Chem., 278(34), gastro-esophageal adenocarcinomas-single center
31745-31755. experiences in the context of current literature.
Front Oncol, 5, 73.
Cho, J. K. (2016). Epstein-Barr Virus-Associated
Gastric Carcinoma and Specific Features of the Ghirelli, C. y Hagemann, T. (2013). Targeting
Accompanying Immune Response. Journal of Gastric immunosuppressionfor cancer therapy. J Clin Invest.,
Cancer, 16(1), 1-7. 123, 2355-2357.

De Groot, D. J., De Vries, E. G., Groen, H. J. y De Jong, Gruhne, B., Sompallae, R., Marescotti, D., Kamranvar,
S. (2007). Non-steroidal anti-inflammatory drugs to S. A., Gastaldello, S. y Masucci, M. G. (2009). The
potentiate chemotherapy effects: from lab to clinic. Epstein-Barr virus nuclear antigen-1 promotes
Crit Rev Oncol Hematol., 61, 52-60. genomic instability via induction of reactive oxygen
species. Proc Natl Acad Sci USA, 106(7), 2313-2318.
De Martel, C., Ferlay, J., Franceschi, S., Vignat, J., Bray,
F., Forman, D. y Plummer, M. (2012). Global burden of Guidotti, L. G. y Chisari, F. V. (2006). Immunobiology
cancers attributable to infections in 2008: a review and pathogenesis of viral hepatitis. Annu Rev Pathol
and synthetic analysis. Lancet Oncol., 13(6), 607-615. Mech Dis., 1, 23-61.

Duensing, S. y Münger, K. (2002). Human Hofseth, L. J. y Ying, L. (2006). Identifying and
papillomaviruses and centrosome duplication defusing weapons of mass inflammation in
errors: modeling the origins of genomic instability. carcinogenesis. Biochim Biophys Acta, 1765, 74-84.
Oncogene, 21(40), 6241-6248.
Iizasa, H. N. (2012). Epstein-Barr Virus (EBV)-
Elgui de Oliveira, D. ( 2007). DNA viruses in human associated Gastric Carcinoma. Viruses, 4(12), 3420-
cancer: an integrated overview on fundamental 3439.

Tequio, vol. 1, no. 2, enero-abril, 2018